Literature DB >> 9764357

Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft.

P Moreau1, P Paul, N Rouas-Freiss, M Kirszenbaum, J Dausset, E D Carosella.   

Abstract

PROBLEM: Human leukocyte antigen (HLA)-G is a major histocompatibility complex class I antigen, which is referred to as nonclassical because it displays a tissue-restricted distribution in the placenta, a reduced cytoplasmic domain, a limited polymorphism, and several isoforms. The HLA-G antigen is thought to play an essential role during pregnancy by protecting the semi-allogeneic fetus from recognition and destruction by maternal immune cells. METHOD OF STUDY: Alternative splicing of HLA-G mRNA was analyzed by Southern blot of reverse transcriptase-polymerase chain reaction products from trophoblasts of the first trimester of gestation and term placenta. The regulation of HLA-G gene expression was investigated by electrophoretic mobility shift assays using nuclear extracts from cells expressing different levels of HLA-G gene activity. Using polymerase chain reaction-single strand conformational polymorphism and sequencing, we studied HLA-G gene polymorphism in families from the Centre d'Etude du Polymorphisme Humain in Paris. To understand the function of the HLA-G molecule, cytotoxicity assays were carried out with peripheral blood mononuclear cells or polyclonal natural killer effectors cells from 30 different donors against HLA-G1 and HLA-G2 transfectants.
RESULTS: Four main aspects have been elucidated: 1) The primary transcript of the HLA-G gene is alternatively spliced into five main mRNA forms: HLA-G1 (full length), HLA-G2 (minus exon 3), which encodes a membrane-bound isoform associated with beta-2 microglobulin, HLA-G3 (minus exons 3 and 4), HLA-G4 (minus exon 4), and HLA-G5 (plus intron 4), which encodes a soluble form of the HLA-G antigen; 2) specific nuclear factors bind to an important regulatory element located more than 1.2 kb from the HLA-G gene. Three specific complexes are observed in cells that show HLA-G transcriptional activity and an additional factor that could correlate with the repression of HLA-G gene expression that is detected in natural killer cells; 3) we observed an important genomic polymorphism in exon 3 but a very low polymorphism at the protein level; 4) HLA-G1 and HLA-G2 transfectants clearly demonstrated that both HLA-G isoforms are capable of inhibiting natural killer lytic activity.
CONCLUSION: These results suggest that HLA-G acts as the public ligand for natural killer inhibitory receptors, thus protecting the fetus against maternal rejection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764357     DOI: 10.1111/j.1600-0897.1998.tb00405.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  8 in total

1.  Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface.

Authors:  Craig S Clements; Lars Kjer-Nielsen; Lyudmila Kostenko; Hilary L Hoare; Michelle A Dunstone; Eric Moses; Katy Freed; Andrew G Brooks; Jamie Rossjohn; James McCluskey
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-17       Impact factor: 11.205

Review 2.  Human embryonic stem cells: potential tool for achieving immunotolerance?

Authors:  Pablo Menendez; Clara Bueno; Lisheng Wang; Mickie Bhatia
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  The production, purification and crystallization of a soluble form of the nonclassical MHC HLA-G: the essential role of cobalt.

Authors:  Craig S Clements; Lars Kjer-Nielsen; Lyudmila Kostenko; James McCluskey; Jamie Rossjohn
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-12-16

4.  Amniotic fluid soluble human leukocyte antigen-G in term and preterm parturition, and intra-amniotic infection/inflammation.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Cristiano Jodicke; Shali Mazaki-Tovi; Edi Vaisbuch; Offer Erez; Pooja Mittal; Francesca Gotsch; Tinnakorn Chaiworapongsa; Sam S Edwin; Percy Pacora; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-12

5.  Increase in concentration of soluble HLA-G in high-quality embryos after intracytoplasmic sperm injection.

Authors:  Mohammad Hassan Heidari; Marefat Ghaffari Novin; Farzaneh Ahmadi; Mehran Khorshid; Tohid Najafi; Aidin Molouki; Saghar Salehpour; Mojgan Bandehpour; Matineh Heidari; Eimi Sato
Journal:  Anat Cell Biol       Date:  2011-12-30

6.  Evolution of the levels of human leukocyte antigen G (HLA-G) in Beninese infant during the first year of life in a malaria endemic area: using latent class analysis.

Authors:  Tania C d'Almeida; Ibrahim Sadissou; Gilles Cottrell; Rachida Tahar; Philippe Moreau; Benoit Favier; Kabirou Moutairou; Eduardo A Donadi; Achille Massougbodji; Nathalie Rouass-Freiss; David Courtin; André Garcia
Journal:  Malar J       Date:  2016-02-09       Impact factor: 2.979

7.  Soluble human leukocyte antigen -G during pregnancy and infancy in Benin: Mother/child resemblance and association with the risk of malaria infection and low birth weight.

Authors:  Tania C d'Almeida; Ibrahim Sadissou; Jacqueline Milet; Gilles Cottrell; Amandine Mondière; Euripide Avokpaho; Laure Gineau; Audrey Sabbagh; Achille Massougbodji; Kabirou Moutairou; Eduardo A Donadi; Benoit Favier; Edgardo Carosella; Philippe Moreau; Nathalie Rouas-Freiss; David Courtin; André Garcia
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

8.  High level of soluble human leukocyte antigen (HLA)-G at beginning of pregnancy as predictor of risk of malaria during infancy.

Authors:  Tania C d'Almeida; Ibrahim Sadissou; Mermoz Sagbohan; Jacqueline Milet; Euripide Avokpaho; Laure Gineau; Audrey Sabbagh; Kabirou Moutairou; Eduardo A Donadi; Benoit Favier; Cédric Pennetier; Thierry Baldet; Nicolas Moiroux; Edgardo Carosella; Philippe Moreau; Nathalie Rouas-Freiss; Gilles Cottrell; David Courtin; André Garcia
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.